Charles Ferté
246 works · 7,871 citations · h-index 35
Top works
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
- Exomics and immunogenics
- High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology
- Hyperprogressive disease: recognizing a novel pattern to improve patient management
- Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials
- Tumour growth rates and RECIST criteria in early drug development
- Molecular circuits of solid tumors: prognostic and predictive tools for bedside use
- Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data
- Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial
- Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial
- Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
- The complexity of tumor shape, spiculatedness, correlates with tumor radiomic shape features
- Natural history, management and pharmacokinetics of Everolimus-induced-oral ulcers: Insights into compliance issues
- Effect of tumor growth rate (TGR) on response patterns of checkpoint inhibitors in non-small cell lung cancer (NSCLC).
- Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy
- Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence
- Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status